Multicenter study on the efficacy and safety of 3 kinds of Cephalosporin for injection from centralized procurement or non-centralized procurement / 中国药房

OBJECTIVE To compare the efficacy and safety of Cefazolin sodium for injection， Cefuroxime sodium for injection， and Ceftazidime for injection from nationally organized centralized drug procurement （hereinafter referred to as “centralized procurement”） and non-centralized procurement in patients with bacterial infection. METHODS The case data of hospitalized patients who had used 3 kinds of Cephalosporins for injection from centralized procurement or non-centralized procurement in the treatment of bacterial infections were retrospectively collected from 19 medical institutions in Kunming from January 2020 to September 2022. After balancing the baseline differences between the groups with the propensity score matching method， the effectiveness and safety differences of 3 kinds of Cephalosporins for injection from centralized procurement or non- centralized procurement were compared respectively. RESULTS After balancing the baseline differences among the groups， 394 cases in each group of Cefazolin sodium for injection from centralized procurement or non-centralized procurement， 472 cases in each group of Cefuroxime sodium for injection from centralized procurement or non-centralized procurement， 504 cases in group of Ceftazidime for injection from centralized procurement and 590 cases in group of non-centralized procurement were included in the analysis. In terms of effectiveness， there were no significant differences in clinical response rate， 72 h response rate， bacterial clearance rate， and the recovery rate of body temperature， white blood cell count， neutrophil count， neutrophil percentage， C-reactive protein， procalcitonin recovery between the centralized procurement group and non-centralized procurement group of Cefazolin sodium for injection and Cefuroxime sodium for injection （P＞0.05）. The proportion of patients in centralized procurement group of Ceftazidime for injection with C-reactive protein restored to normal reference range was significantly higher than that in non-centralized procurement group （46.9% vs. 27.9%， P＜0.05）， but there were no statistically significant differences in other effectiveness indicators among groups （P＞0.05）. In terms of safety， there was no statistical difference in the incidence of adverse drug reactions between centralized procurement group and non-centralized procurement group of 3 kinds of Cephalosporins for injection （P＞0.05）； the incidence of platelet count reduction in centralized procurement group of Cefazolin sodium for injection was significantly higher than non-centralized procurement group （20.7% vs. 7.1%， P＜0.05）， the incidence of eosinophilia elevation in centralized procurement group of Ceftazidime for injection was significantly higher than non-centralized procurement group （5.3% vs. 1.9%， P＜0.05）. In addition， there was no statistically significant difference in the abnormal rates of other laboratory indicators among the three types of injection Cephalosporins （P＞ 0.05）. CONCLUSIONS The efficacy of 3 kinds of Cephalosporin for injection from centralized procurement is not inferior to non- centralized procurement varieties， and the safety is equivalent to that of non-centralized procurement varieties.

Research progress on the role of miR-155 in rejection of organ transplantation / 器官移植

Rejection has constantly been an unresolved challenge in the field of organ transplantation. The research on the mechanism of rejection plays a significant role in improving the efficacy of organ transplantation and enhancing the survival rate of graft. The innate and specific immune responses of the human body jointly participate in the graft rejection, leading to graft injury. In recent years, multiple researchers have conducted in-depth studies on the mechanism underlying the role of microRNA (miR) in regulating rejection. Among them, miR-155 has been widely considered as a key factor involved in immune regulation. The expression level and functional status of miR-155 may be intimately associated with the occurrence of rejection, which may become a new target for overcoming rejection. In this article, relevant studies on the role of miR-155 in regulating key immune cells in innate and specific immune responses were reviewed, aiming to provide novel ideas for the development of new immunosuppressants and rejection therapy.

Research progress on the gene polymorphism of tacrolimus transporter in organ transplantation / 器官移植

Tacrolimus (Tac) is a commonly used immunosuppressant after organ transplantation, which has high immunosuppressive efficacy. However, the pharmacokinetics of Tac significantly differ among individuals, and gene polymorphism is the main influencing factor. In recent years, the gene polymorphism of drug transporter has become a novel research hotspot. Nevertheless, the effect of the gene polymorphism of transporter on Tac pharmacokinetics remains controversial. Consequently, the correlation between the gene polymorphism of transporter and Tac blood concentration plays a significant role in guiding Tac-based individualized immunosuppressive therapy. In this article, the research progresses on the gene polymorphism of adenosine triphosphate-binding cassette (ABC) transporter and solute carrier (SLC) transporter in organ transplantation was reviewed. The correlation between the gene polymorphism of transporter and Tac blood concentration was summarized, aiming to provide reference for Tac-based individualized therapy.

Potential efficacy of immunosuppressant in the treatment of COVID-19 / 中华微生物学和免疫学杂志

The outbreak of COVID-19 has infected millions of people and caused hundreds of thousands of deaths worldwide. As there is no specific medicines or effective vaccines against 2019-nCoV at present, it is an alternative strategy to repurpose existing drugs for new diseases. Cyclosporin A inhibits the replication of coronaviruses by binding to cellular cyclophilins. Chloroquine/hydroxychloroquine can block virus-receptor binding through interfering with terminal glycosylation of the cellular receptor angiotensin-converting enzyme 2 (ACE2). Trastuzumab prevents the binding of IL-6 to both sIL-6R and mIL-6R and thereby inhibits the cytokine storm syndrome induced by COVID-19. This paper discussed the potential anti-2019-nCoV effects of some common immunosuppressant including cyclosporine, chloroquine/hydroxychloroquine, and tocilizumab.

Effect of second line treatment with S-1 and thalidomide in patients with advanced pancreatic cancer / 中华胰腺病杂志

Objective To investigates the efficacy and tolerability of second line treatment with S-1 plus thalidomide in patients with advanced pancreatic cancer.Methods Sixty patients hospitalized in Department of Oncology of Cangzhou Central Hospital from July 2010 to October 2012 were included in this study.All the patients were diagnosed as having pancreatic carcinoma.The patients were randomly divided into two groups,one group was treated with S-1 alone,and the other group was treated with S-1 plus thalidomide.Then the efficacy and toxicity of two groups was evaluated.Results The disease control rates were 36.7％ and 46.7％ in the S-1 alone group and the S-1 plus thalidomide group,and the difference between the two groups was not statistically significant (P =0.31).The progression free survival (PFS) was 2.9 months and 3.3 months,and the difference between the two groups was statistically significant (P ＜ 0.05),the Karnofsky score,pain,sleep and weight improvement rate was 63.3％,46.7％,66.7％ and 53.3％ in combination group,which were significantly better than those in control group (30.0％,13.3％,30.0％ and 20.0％),and the difference between the two groups was statistically significant (P ＜ 0.05).The major adverse events were nausea,vomiting,fatigue and drowsiness,mainly of grades Ⅰ ～ Ⅱ.Conclusions S-1 plus thalidomide as second line treatment of pancreatic cancer can prolong the PSF of patients with advanced pancreatic cancer with excellent safety,and patients' quality of life is also improved.

The effect of thalidomide combined with radiation therapy on growth and radiosensization on xenograft tumor of colonic carcinoma / 中国癌症杂志

Background and purpose:Thalidomide can enhance the radiation sensitivity on tumor effectively, but the mechanism of radiosensitization is still unclear. The present study aimed to investigate whether thalidomide could enhance the radiation sensitivity on colon cancer transplanted tumor of mouse, and to investigate the underlying mechanism. Methods: We established the model of colon26 colonic carcinoma, and the mice were divided into 4 groups:Control group, the thalidomide group, the radiotherapy group and thalidomide+radiotherapy group. From the day of treatment, tumors were measured every other day. Then, the xenograft tumor growth curve was depicted. Tumor volumes were measured in different treatment groups, then, the inhibitory rates of tumor growth were calcutated. Using immunohistochemical method in to detect the expression of microvessel density (MVD) in tumor tissue. Results:The mean tumor volumes at day 22 were (4.97±1.20)cm3 (control group), (2.90±0.92)cm3 (T group), (2.66±0.88)cm3 (R group), and (1.89±0.76)cm3 (T+R group). The tumor inhibition rate in the combination group (61.9%) was signiifcantly higher than the other groups (41.7%, 46.5%, P<0.05). The radiotherapy sensitization enhancement ratio of the combined treatment group was 2.27 times than in the radiotherapy group. Thalidomide combined with radiation therapy can significantly inhibit microvessel density of tumor:The decreasing MVD of T+R group, T group and R group were respectively 46.8%, 40.7%and 37.7%, and there was statistical significance between T+R group and T group (P<0.05 ), so as between T+R group and R group. It could be found more necrotic cells in tumor of group, and there was statistical signiifcance between T+R group and control group (P<0.05). Conclusion:Thalidomide can enhance the radiosensitivity mice of colonic carcinoma, and its mechanism may be related to the inhibition of tumor angiogenesis related.

Analysis of set-up accuracy of two body membrane fixation methods in radiotherapy for thoracic neoplasms / 中华放射肿瘤学杂志

Objective To study the set-up accuracy in radiotherapy of thoracic neoplasms by improving the body immobilization method.Methods Fifty patients with thoracic neoplasms were randomly divided into conventional group (without electrode paste) and improved group (with electrode paste).Using simulator for position calibration and center field digital image reconstruction from treatment planning system.Then compare the set-up accuracy of two groups with different body methods by grouped t-test.Results Set-up error in the left-right,superior-inferior,anterior-posterior direction were 2.5 ± 1.5 and 2.4 ± 1.4(P =0.010),4.4 ± 2.0 and 2.2 ± 1.2 (P =0.000),2.2 ± 1.3 and 2.1 ± 1.0 (P =0.100) in conventional group and improved group,respectively.Conclusions The improved body immobilization method improves setup accuracy in radiotherapy for thoracic neoplasms which also will be effective for clinical treatment.

Impact of implanted metal plates on radiation dose distribution in vivo / 中华放射肿瘤学杂志

Objective To investigate the impact of metal plate on radiation dose distribution in surrounding tissues in cadaver specimens.Methods Stainless steel plate, titanium plate, and muscle strip were implanted into the left thigh of a corpse, respectively.All the specimens were irradiated with 6 MV X-ray , SSD = 100 cm.The absorbed dose of surface was measured by thermoluminiscent elements.Results Surface dose distributions differed significantly among the three different materials (F = 57.35, P < 0.01),with the amounts of 1.18 Gy ± 0.04 Gy (stainless steel plate), 1.12 Gy ± 0.04 Gy (titanium plate) and 0.97 Gy ±0.03 Gy (muscle strip), respectively.The surface absorbed doses on incident plane of stainless steel plate and titanium plate were significantly increased by 21.65% and 15.46% respectively as compared with that of muscle strip.The absorbed doses on the exit surface of stainless steel plate, titanium plate and muscle strip were 0.87 Gy ± 0.03 Gy, 0.90 Gy ± 0.02 Gy and 0.95 Gy ± 0.04 Gy, respectively (F =13.37, P <0.01).The doses on the exit surface of stainless steel plate and titanium plate were significantly lowered by 8.42% and 5.26% when compared with that of muscle strip.Using treatment planning system,the differences between dose distribution with and without metal plate were compared.Within 1 cm away from the incident plate, there was an obvious increase in the absorbed dose, while the influence was less than 5% 1cm outside the surface.The effect of dose distribution on exit surface was less than 2%.Conclusions The influence of metal plate on the radiotherapy dose distribution is significant.The deviations ranges from 5% to 29%.Under the same condition, the impact of stainless steel plate is much more than that of titanium alloy plate.

Utilization of Antihypertensive Drugs in Our Hospital from Jun. 2004 to Dec. 2006 / 中国药房

OBJECTIVE:To investigate the feature and tendency of the application of antihypertensive drugs in our hospital.METHODS:The utilization of antihypertensive drugs in our hospital from Jun.2004 to Dec.2006 was analyzed statistically in respect of the consumption sum and DDDs etc.RESULTS:The first line drugs used most frequently in our hospital were beta receptor antagonists,AGT Ⅱ antagonists,ACEI,a calcium antagonist etc.Leading the first place on the list of DDDs was indapamide because of its good safety and efficacy.Mesylate amlodipine,felodipine,irbesartan,perindopril,metoprolol tartrate,indapamide,bisoprolol fumarate,losartan/hydrochlorothiazide ranked among the first 10 places in either DDDs or consumption sum.CONCLUSION:The antihypertensive drugs are characterized by complicated categorization,wide variety,and widespread clinical application,and the use of which in our hospital is basically rational.

Modified Stamey bladder neck suspension for type Ⅰ femal stress urinary incontinence:early and long-term analysis / 中华泌尿外科杂志

0.25. Conclusions Modified Stamey bladder neck suspension is an effective treatment for type Ⅰ female stsees urinary incontinence.